Mycophenolate Mofetil Therapy in Refractory Inflammatory Eye Disease

Por: Cuchacovich, M (Cuchacovich, Miguel)¹; Solanes, F (Solanes, Federica)²; Perez, C (Perez, Claudio)³; Verdaguer, JI (Ignacio Verdaguer, Juan)¹; Verdaguer, J (Verdaguer, Juan)³; Castiglione, E (Castiglione, Enzo)²; Carpenter, C (Carpentier, Cristian)³; Traipe, L (Traipe, Leonidas)³; Villarroel, F (Villarroel, Francisco)³

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Volumen: 32
Número: 1
Páginas: 55-61
DOI: 10.1089/jop.2015.0044
Fecha de publicación: JAN 1 2016

Resumen

Purpose: To study the efficacy and incidence of treatment-related side effects of mycophenolate mofetil (MMF) therapy in patients with noninfectious inflammatory eye diseases. Methods: Retrospective cohort study of 27 Chilean patients treated for noninfectious inflammatory eye diseases using MMF therapy over a 10-year period. Main outcome measures were: ability to control ocular inflammation and to taper prednisone to 10mg daily (treatment success); incidence of treatment-related side effects. Results: The proportion of patients with sustained control of inflammation was 81.48% at 6 months. Additionally 55.56% and 22.22% of patients succeeded in tapering their prednisone to 5-10mg/day and <5mg/day, at 6 months. Two patients developed a neoplasia during MMF therapy; however, this cohort is too small to interpret the significance of this relation to MMF treatment. Conclusions: MMF seems to be an effective corticosteroid-sparing agent with an acceptable safety profile.

Palabras clave

KeyWords Plus: SYSTEMIC-LUPUS-ERYTHEMATOSUS; RENAL-ALLOGRAFT RECIPIENTS; IMMUNOSUPPRESSIVE THERAPY; UVEITIS; DISORDERS; SCLERITIS; EFFICACY; AGENT

Información del autor

Dirección para petición de copias: Cuchacovich, M (autor para petición de copias)


Direcciones:
